Biomarker Identification of Tear FluidFumio Tsuji* and Kouichi Kawazu
Ophthalmic Research and Development Center, Santen Pharmaceutical Co. Ltd., 8916-16 Takayama-cho, Ikomashi, Nara 630-0101, Japan
- *Corresponding Author:
- Dr. Fumio Tsuji
Ophthalmic Research and Development Center
Santen Pharmaceutical Co. Ltd
8916-16 Takayama-cho, Ikoma-shi
Nara 630-0101, Japan
Tel: +81-743-79 4552
E-mail: [email protected]
Received date: December 12, 2011; Accepted date: January 21, 2012; Published date: January 23, 2012
Citation: Tsuji F, Kawazu K (2012) Biomarker Identification of Tear Fluid. Metabolomics 2:105. doi:10.4172/2153-0769.1000105
Copyright: © 2012 Tsuji F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
While some potential biomarkers for ocular diseases have been reported, it is difficult to select a single biomarker that is most important in each ocular disease. After reviewing multiple biomarker studies conducted on small sample subgroups, we concluded that newer analysis techniques may result in different and more specific findings. While progress has been made in developing various omics studies, studies comparing tears of normal and diseased eyes are still lacking. Preliminary omics studies suggest the importance of further studies aimed at identifying potential ocular-associated lipid, non-lipid/protein, and protein biomarkers. In addition, combining potential biomarkers might be a good strategy for the diagnosis and assessment of ocular diseases.